The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia

Therapeutic Advances in Hematology

Volumn 6, Issue 5, 2015, Pages 253-261

  Yilmaz, Musa ^a   Richard, Samantha ^b   Jabbour, Elias ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute lymphoblastic leukemia; inotuzumab ozogamicin; refractory; relapsed; salvage

Indexed keywords

EID: 84993790947     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620715596715     Document Type: Review

References (30)

1. Advani A. Coiffier B. Czuczman M. Dreyling M. Foran J. Gine E. et al. (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 28: 2085–2093.
2. Advani A. Stein A. Kantarjian H. (2014) A phase II study of weekly inotuzumab ozogamicin (INO) in adult patients with CD22-positive acute lymphoblastic leukemia (ALL) in second or later salvage. 56th ASH Annual Meeting and Exposition, 6–9 December, San Francisco, abstract 2255.
3. Bene M. Kolopp Sarda M. El Kaissouni J. de March Kennel A. Mole C. Kohler C. et al. (1998) Automated cell count in flow cytometry: a valuable tool to assess CD4 absolute levels in peripheral blood. Am J Clin Pathol 110: 321–326.
4. Cao Y. Jusko W. (2014) Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn 41: 375–387.
5. Carreras E. Bertz H. Arcese W. Vernant J. Tomas J. Hagglund H. et al. (1998) Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for blood and marrow transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92: 3599–3604.
6. Dijoseph J. Armellino D. Boghaert E. Khandke K. Dougher M. Sridharan L. et al. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103: 1807–1814.
7. Faderl S. Jain N. O'Brien S. Thomas D. (2013) Inotuzumab ozogamicin (CMC-544) compared to chemotherapy in patients (pts) with relapsed / refractory (R/R) acute lymphoblastic leukemia (ALL): a retrospective comparison. J Clin Oncol 31 (Suppl.): abstract 7095.
8. Fielding A. Richards S. Chopra R. Lazarus H. Litzow M. Buck G. et al. (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109: 944–950.
9. Hamann P. Hinman L. Hollander I. Beyer C. Lindh D. Holcomb R. et al. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13: 47–58.
10. Jabbour E. O'Brien S. Huang X. Thomas D. Rytting M. Sasaki K. et al. (2015) Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol 90: 193–196.
11. Jabbour E. O'Brien S. Thomas D. Kantarjian H. (2014 a) Inotuzumab ozogamicin in combination with low-intensity chemotherapy (Mini-Hyper-Cvd) as frontline therapy for older patients (⩾60 years) with acute lymphoblastic leukemia (ALL). 56th ASH Annual Meeting and Exposition, 6–9 December, San Francisco, abstract 794.
12. Jabbour E. O'Brien S. Thomas D. Kantarjian H. (2014 b) Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as salvage therapy for adult patients with refractory / relapse (R/R) acute lymphoblastic leukemia (ALL). 56th ASH Annual Meeting and Exposition, 6–9 December, San Francisco, abstract 964.
13. Johnson D. Savani B. (2012) How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation? Exp Hematol 40: 513–517.
14. Kantarjian H. Thomas D. Jorgensen J. Jabbour E. Kebriaei P. Rytting M. et al. (2012 a) Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13: 403–411.
15. Kantarjian H. Thomas D. Jorgensen J. Kebriaei P. Jabbour E. Rytting M. et al. (2013) Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119: 2728–2736.
16. Kantarjian H. Thomas D. O'Brien S. Cortes J. Giles F. Jeha S. et al. (2004) Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101: 2788–2801.
17. Kantarjian H. Thomas D. Wayne A. O'Brien S. (2012 b) Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol 30: 3876–3883.
18. Kebriaei P. Wilhelm K. Ravandi F. Brandt M. de Lima M. Ciurea S. et al. (2013) Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk 13: 296–301.
19. Kozlowski P. Astrom M. Ahlberg L. Bernell P. Hulegardh E. Hagglund H. et al. (2012) High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003–2007. Haematologica 97: 1414–1421.
20. Larson R. Sievers E. Stadtmauer E. Lowenberg B. Estey E. Dombret H. et al. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104: 1442–1452.
21. Lee J. Gooley T. Bensinger W. Schiffman K. Mcdonald G. (1999) Veno-occlusive disease of the liver after usulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 5: 306–315.
22. Lobo E. Hansen R. Balthasar J. (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93: 2645–2668.
23. Matsui H. Takeshita A. Naito K. Shinjo K. Shigeno K. Maekawa M. et al. (2002) Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and / or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 16: 813–819.
24. O'Reilly M. Paulson J. (2009) Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci 30: 240–248.
25. Piccaluga P. Arpinati M. Candoni A. Laterza C. Paolini S. Gazzola A. et al. (2011) Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma 52: 325–327.
26. Ricart A. (2011) Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 17: 6417–6427.
27. Shan D. Press O. (1995) Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol 154: 4466–4475.
28. Takeshita A. Shinjo K. Naito K. Matsui H. Sahara N. Shigeno K. et al. (2005) Efficacy of gemtuzumab ozogamicin on atra- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 19: 1306–1311.
29. Takeshita A. Shinjo K. Yamakage N. Ono T. Hirano I. Matsui H. et al. (2009) CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol 146: 34–43.
30. Thomas D. Kantarjian H. Smith T. Koller C. Cortes J. O'Brien S. et al. (1999) Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 86: 1216–1230.